SLC2A1 and cancer: This combination therapy uniquely downregulates the survival signal glucose transporter 1 (Glut-1), crucial for cancer cell glucose metabolism, while upregulating p21, a cell cycle inhibitor protein often dysregulated in cancer cells [90].